Moetaz El-Domyati, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt; Tarek S. El-Ammawi, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt; Walid Medhat, MD, Department of Dermatology, Al-Minya University, Al-Minya, Egypt, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania; Osama Moawad, MD, Moawad Skin Institute for Laser, Cairo, Egypt; My G. Mahoney, PhD, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania; Jouni Uitto, MD, PhD, Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania Read the rest of this article »

Mark S. Nestor, MD, PhD, Center for Clinical and Cosmetic Research (CCCR), Aventura, Florida; Mark A. Stillman, PhD, Center for Clinical and Cosmetic Research (CCCR), Aventura, Florida; Andrew C. Frisina, Syracuse University, Syracuse, New York Read the rest of this article »

Michael H. Gold, MD, Gold Skin Care Center, Nashville, Tennessee, Tennessee Clinical Research Center, Nashville, Tennessee; Bruce E. Katz, MD, Juva Skin & Laser Center, New York, New York; Joel L. Cohen, MD, AboutSkin Dermatology and DermSurgery, Englewood, Colorado; Julie Biron, Tennessee Clinical Research Center, Nashville, Tennessee Read the rest of this article »

Douglas Mest, MD; Gail Humble, MD, Blue Pacific Aesthetic Medical Group, Hermosa Beach, California

Abstract
Injectable poly-L-lactic acid is United States Food and Drug Administration–approved for the restoration and/or correction of the signs of lipoatrophy in people with human immunodeficiency virus and for use in immune-competent people for the correction of nasolabial fold contour deficiencies. Current prescribing information recommends using either a tunneling or threading technique in a grid or cross-hatched pattern or a depot technique (in thin skin areas) to administer multiple passes of injectable poly-L-lactic acid per treatment session via a 26-gauge needle. A review of the literature and the recently published guidelines from the American Society for Dermatologic Surgery provide evidence to support the use of a cross-fanning technique with a 25-gauge needle. In conclusion, the use of a cross-fanning injection technique with a 25-gauge needle to administer injectable poly-L-lactic acid provides a clinically valid, alternate delivery option for the treatment of patients with human immunodeficiency virus-associated lipoatrophy.
(J Clin Aesthet Dermatol. 2010;3(12):43–49.) Read the rest of this article »

LindaSusan Marcus, MD; Private Practice, Wyckoff, New Jersey; Director–Chair, Department of Dermatology, Valley Hospital, Ridgewood, New Jersey;Neal Carlin, BS, LindaSusan Marcus, MD, Wyckoff, New Jersey; Robert Carlin, MA, LindaSusan Marcus, MD, Wyckoff, New Jersey.

Disclosure: The authors report no relevant conflicts of interest. Read the rest of this article »